Abstract
1 The aggregation response of platelets induced by 5-HT was greatly increased in psychiatric patients receiving chlorpromazine therapy when compared with normal volunteers and psychiatric patients not receiving chlorpromazine. 2 Platelet aggregation responses to ADP were normal during chlorpromazine therapy, but 5-HT induced aggregation was increased in rate and the typical transient reversible response was converted to an irreversible response in all subjects. This was usually indistinguishable from the ADP response. 3 When chlorpromazine therapy was stopped, plasma concentrations of chlorpromazine, monodesmethylchlorpromazine and chlorpromazine sulphoxide fell rapidly within one week, whereas 5-HT induced platelet aggregation responses became normal after three weeks. The enhanced responses returned when chlorpromazine therapy was re-instituted. 4 It is possible that platelet aggregation responses to 5-HT in vitro could prove to be a useful index of the pharmacological effect of chlorpromazine in vivo.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baumgartner H. R. 5-Hydroxytryptamine uptake and release in relation to aggregation of rabbit platelets. J Physiol. 1969 Apr;201(2):409–423. doi: 10.1113/jphysiol.1969.sp008763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baumgartner H. R., Born G. V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature. 1968 Apr 13;218(5137):137–141. doi: 10.1038/218137a0. [DOI] [PubMed] [Google Scholar]
- Baumgartner H. R., Born G. V. The relation between the 5-hydroxytryptamine content and aggregation of rabbit platelets. J Physiol. 1969 Apr;201(2):397–408. doi: 10.1113/jphysiol.1969.sp008762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Besterman E. M., Gillett M. P. Influence of lysolecithin on platelet aggregation initiated by 5-hydroxytryptamine. Nat New Biol. 1973 Feb 14;241(111):223–224. doi: 10.1038/newbio241223a0. [DOI] [PubMed] [Google Scholar]
- Boullin D. J., Green A. R., Price K. S. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol. 1972 Mar;221(2):415–426. doi: 10.1113/jphysiol.1972.sp009758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Curry S. H. Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med. 1971 Mar;64(3):285–289. doi: 10.1177/003591577106400323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Curry S. H. Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem. 1968 Jul;40(8):1251–1255. doi: 10.1021/ac60264a031. [DOI] [PubMed] [Google Scholar]
- O'BRIEN J. R. A COMPARISON OF PLATELET AGGREGATION PRODUCED BY SEVEN COMPOUNDS AND A COMPARISON OF THEIR INHIBITORS. J Clin Pathol. 1964 May;17:275–281. doi: 10.1136/jcp.17.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sakalis G., Chan T. L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia. 1973 Sep 28;32(3):279–284. doi: 10.1007/BF00422150. [DOI] [PubMed] [Google Scholar]
- Usdin E. The assay of chlorpromazine and metabolites in blood, urine, and other tissues. CRC Crit Rev Clin Lab Sci. 1971 Sep;2(3):347–391. doi: 10.3109/10408367109151312. [DOI] [PubMed] [Google Scholar]